AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

Trial Identifier: D7230C00001
Sponsor: AstraZeneca
NCTID:: NCT06106945
Start Date: December 2023
Primary Completion Date: November 2025
Study Completion Date: November 2025
Condition: Myeloma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Melbourne, AU, 3000
AU Perth, AU, WA 6009
CA, ON Hamilton, ON, CA, L8V 5C2
CA, Québec Montreal, Québec, CA, H4A 3J1
CN Beijing, CN, 100044
DE Freiburg, DE, 79106
DE Hamburg, DE, 20246
DE Lübeck, DE, 23538
DE Nürnberg, DE, 90419
DE Wuerzburg, DE, 97080
ES Madrid, ES, 28041
ES Pamplona, ES, 31005
ES Salamanca, ES, 37007
FR Lille, FR, 59037
FR Nantes, FR, 44000
JP Kashiwa, JP, 277-8577
JP Nagoya-shi, JP, 467-8602
JP Yamagata-shi, JP, 990-9585
US, CA Duarte, CA, US, 91010
US, CA Irvine, CA, US, 92618
US, GA Atlanta, GA, US, 30322
US, MI Ann Arbor, MI, US, 48109
US, MO Saint Louis, MO, US, 63110
US, NY New York, NY, US, 10065
US, PA Philadelphia, PA, US, 19104
US, VA Fairfax, VA, US, 22031